Sugi Predict

Sugi Predict / Compounds / SCHEMBL2006125

SCHEMBL2006125

SCHEMBL2006125

OCCCC(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 15/20 0.56
▸ CHRM3 P20309 15/20 0.56
▸ CHRM5 P08912 14/20 0.56
▸ CHRM2 P08172 14/20 0.56
▸ CHRM1 P11229 14/20 0.56
▸ SIGMAR1 Q99720 2/20 0.55
▸ HTR1A P08908 2/20 0.53
▸ CYP2D6 P10635 2/20 0.53
▸ OPRM1 P35372 2/20 0.53
▸ KCNH2 Q12809 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ DRD2 P14416 1/20 0.53
▸ DRD1 P21728 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ DRD3 P35462 1/20 0.53
▸ SCN1A P35498 1/20 0.53
▸ SCN2A Q99250 1/20 0.53
▸ SCN3A Q9NY46 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ LMNA P02545 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6048472 0.98 SIGMAR1 (0.58) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL28363183 0.90 CHRM4 (0.49) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL4431781 0.88 SIGMAR1 (0.66) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL301346 0.86 SMN1; SMN2 (0.55) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL6551716 0.84 KIF11 (0.61) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL560935 0.83 SMN1; SMN2 (0.61) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL7453762 0.82 KIF11 (0.59) CHRM4CHRM3CHRM5CHRM2CHRM1
Ammonia Solution, Strong SCHEMBL2922340 0.82 KIF11 (0.59) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL11495018 0.80 CHRM4 (0.41) CHRM4CHRM3CHRM5CHRM2CHRM1
SCHEMBL5596560 0.80 CHRM4 (0.38) CHRM4CHRM3CHRM5CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013008044-A1 SYNTHESIS OF (+) AND (-) 1 -(5,5-DIPHENYLTETRAHYDROFURAN-3- YL)-N,N-DIMETHYLMETHANAMINE, (+) AND (-) 1-(2,2-DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHANAMINE AND (+) AND (-) 1-(2,2- DFFHENYLTETRAHYDROFURAN-3-YL)-N-METIHYLMETHANAMINE ANAVEX LIFE SCIENCES CORP. (GR) 2013-01-17 — — WO claimed
EP-4508101-B1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2026-03-25 — — EP disclosed
EP-4709518-A1 PROCESS FOR THE PREPARATION OF POLYISOBUTENE FROM OLEFINS FROM ISOBUTANOL OBTAINED FROM MIXED GUERBET REACTION OF ETHANOL AND METHANOL BASF SE (DE) 2026-03-18 — — EP disclosed
EP-4667447-A1 PROCESS FOR THE PREPARATION OF POLYISOBUTENE FROM BIO-BASED OLEFINS FROM PRIMARY ALCOHOL BASF SE (DE) 2025-12-24 — — EP disclosed
US-20250250382-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-08-07 — — US disclosed
US-20250250403-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-08-07 — — US disclosed
US-20250179224-A1 MEDIUM MOLECULAR POLYISOBUTENE WITH A CERTAIN DISTRIBUTION OF DOUBLE BOND ISOMERS BASF SE (DE) 2025-06-05 — — US disclosed
US-20250145742-A1 MEDIUM MOLECULAR POLYISOBUTENE WITH A HIGH CONTENT OF CERTAIN DOUBLE BOND ISOMERS BASF SE (DE) 2025-05-08 — — US disclosed
WO-2025082909-A1 PROCESS FOR IMPROVING THE STABILITY OF POLYISOBUTENES BASF SE (DE) 2025-04-24 — — WO disclosed
EP-4508101-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-02-19 — — EP disclosed
US-20100249393-A1 COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES BERRY AND ASSOCIATES, INC. (US) 2010-09-30 — — US disclosed
US-20100249393-A1 COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES BERRY AND ASSOCIATES, INC. (US) 2010-09-30 — — US disclosed
US-7247645-B2 Dihydropyridine derivatives AJINOMOTO CO., INC. (JP) 2007-07-24 — — US disclosed
CN-1871529-A Optical film for display devices EASTMAN KODAK CO (US) 2006-11-29 — — CN disclosed
US-20020147222-A1 Dihydropyridine derivatives AJINOMOTO CO. INC (JP) 2002-10-10 — — US disclosed
EP-1191021-A1 DIHYDROPYRIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-03-27 — — EP disclosed
US-5932573-A Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof WARNER-LAMBERT COMPANY (US) 1999-08-03 — — US disclosed
US-5767129-A TREATING CEREBROVASCULAR DISORDERS, PAIN, CEREBRAL ISCHEMIA WARNER-LAMBERT COMPANY (US) 1998-06-16 — — US disclosed
EP-0561758-A2 Method of preparing optically active homo-beta-amino acids MONSANTO COMPANY (US) 1993-09-22 — — EP disclosed
US-3940446-A Dehydrogenation of alcohols UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249393-A1 COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES RNGTT, OGA, HCCS CHRM4 4194/4885CHRM3 4359/4885CHRM5 4488/4885
US-20020147222-A1 Dihydropyridine derivatives CACNA1B, CACNA1D, CACNA1C CHRM4 1397/4885CHRM3 1329/4885CHRM5 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.